Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    10561265 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (young TIL)
2 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
3 Completed
Has Results
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
4 Recruiting Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
5 Suspended Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Conditions: Skin Cancer;   Metastatic Melanoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IL-12 transduced TIL
6 Terminated
Has Results
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15

Indicates status has not been verified in more than two years